Class / Patent application number | Description | Number of patent applications / Date published |
424253100 | Bordetella (e.g., Bordetella bronchiseptica, etc.) | 11 |
424254100 | Bordetella pertussis | 11 |
20080274145 | Deacylation of Lps in Gram Negative Bacteria - The current invention provides new Gram negative polypeptides exhibiting lipid A 3-O-deacylase activity and are capable of modifying and/or detoxifying gram negative LPS. The present invention also provides Gram negative bacteria, Gram negative bacterial lipopolysaccharides (LPS) and compositions comprising LPS, which are provided with or treated with a 3-O-deacylase activity according to the invention and which may be used for pharmaceutical and/or veterinary purposes, in particular for the preparation of whole cell or acellular vaccines against pathogenic Gram negatives such as | 11-06-2008 |
20100055134 | Method of separating protective components of bordetella pertussis - To provide a method of efficiently separate protective components of | 03-04-2010 |
20100112009 | Acellular antibordetella vaccine - The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of | 05-06-2010 |
20100260803 | Bordetella Parapertussis Whole-Cell Vaccine Composition - An objective of the present invention is to provide a whole-cell bacterial vaccine composition for preventing whooping cough caused by | 10-14-2010 |
20100291153 | VACCINES AGAINST BORDETELLA PERTUSSIS BASED ON LPS GLYCOSYLTRANSFERASE MUTANTS - The invention relates to an improved vaccine against | 11-18-2010 |
20110070265 | ENGINEERED PERTACTIN VARIANTS FOR VACCINE USE - The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against | 03-24-2011 |
20120121647 | INFLUENZA VACCINE, COMPOSITION, AND METHODS OF USE - The invention relates to compositions and vaccines that include a mutated | 05-17-2012 |
20140065187 | Hyperbaric Device and Methods for Producing Inactivated Vaccines and for Refolding/Solubilizing Recombinant Proteins - The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions. | 03-06-2014 |
20160000896 | Hyperbaric Device and Methods for Producing Inactivated Vaccines and for Refolding/Solubilizing Recombinant Proteins - The invention relates to hyperbaric devices for inactivating microorganisms and viruses while retaining their immunogenicity and for making and producing the soluble, disaggregated, refolded or active immunogenic or therapeutic proteins from inclusion bodies produced from prokaryotes or eukaryotes. The invention encompasses hyperbaric methods for inactivating pathogenic organisms, and methods for producing vaccine compositions using the inactivated pathogens. The hyperbarically inactivated microorganisms are safer and more immunogenic than chemically inactivated microorganisms. Similarly, the solubilized proteins have superior properties compared to more heavily aggregated proteins, including reduced non-specific immune reactions. | 01-07-2016 |
20160002691 | IMMUNOTHERAPEUTIC POTENTIAL OF MODIFIED LIPOOLIGOSACCHARIDES/LIPID A - Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases. | 01-07-2016 |
20160045587 | Attenuated Bordetella Strains | 02-18-2016 |